Outcomes of Ranibizumab Biosimilar SB11 in Macular Edema Secondary to Retinal Vein Occlusion

Purpose: To evaluate the outcomes of SB11, a ranibizumab biosimilar, in patients with macular edema secondary to retinal vein occlusion.Methods: This retrospective study included 23 treatment-naïve patients (23 eyes) with macular edema secondary to branch retinal vein occlusion (n = 15) or central retinal vein occlusion (n = 8).All patients received an intravitreal SB11 injection as initial treatment and were followed for a mean of 11.2 ± 7.6 months.Additional injections were administered as needed.Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated at baseline, after the first injection, and at the final follow-up. Results:The mean logarithm of the minimum angle of resolution BCVA improved significantly from 0.74 ± 0.51 at baseline to 0.49 ± 0.40 after the first injection (p < 0.001), and the improvement was maintained at the final follow-up (0.56 ± 0.59).Mean CRT decreased significantly from 640.0 ± 248.7 µm at baseline to 234.7 ± 49.7 µm after the first injection and 250.2 ± 116.0 µm at the final follow-up (p < 0.001).Complete resolution of retinal fluid after a single injection was achieved in 69.6% of eyes; however, recurrence occurred in 68.8% of these eyes during follow-up.In subgroup analyses, both the branch retinal vein occlusion and central retinal vein occlusion groups showed significant reductions in CRT, whereas significant improvement in BCVA at the final follow-up was observed only in the branch retinal vein occlusion group.Conclusions: SB11 was associated with significant anatomical improvement in patients with macular edema secondary to retinal vein occlusion, and significant visual improvement was also observed in the branch retinal vein occlusion group.These findings suggest that SB11 may be an effective therapeutic option for macular edema secondary to retinal vein occlusion.